In silico docking analysis of newly formulated agonist,Ammonio Cyclopentyl Sulfonate (ACS) for humanMetabotropicGlutamate Receptor 7 (GRM7) and its drug likeliness properties.
Prasanna Rajagopalan, Balasubramanian Meenakshisundaram
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, (SAUDIARABIA)
2Department of Geriatrics, Bioinformatics Program, University of Arkansas for Medical Sciences and University of Arkansas at Little Rock, AR 72205, (USA)
Glutamate is the most abundant neurotransmitter in the central nervous system and metabotropic glutamate receptor 7(GRM7) play a vital role in the mediation of excitatory neurotransmission. Any impairment in GRM7 may lead to many neurodisorders like Parkinson’s disease, Alzheimer’s disease and epilepsy. In this study we analyzed the 3D structure of GRM7 and developed a new agonist Ammonio Cyclopentyl Sulfonate (ACS) which will enhance its activity. Also we demonstrated the binding affinity ofACS towards GRM7. Drug likeliness property of ACS was also evaluated. Our results suggest ACS can be used as an agonist to treat neurodisorders thereby act as a neuroprotective agent.
Glutamate; Metabolic neuro disorders; Metabotropic glutamate receptors; GRM7; Agonist; Neurotransmission; Drug likeliness;